Curetis, a Germany-based medical device company, has raised €12.5m ($15m) in its series B round from a consortium including Switzerland-based drugs company Roche’s corporate venturing unit.

Alongside Roche Venture Fund in the B round, were investment firm HBM Partners (founded by Henri B Meier, a former member of the Roche Group executive committee for more than 16 years), which invested €6m, Aeris Capital (the family office of Germany-based software provider SAP co-founder Klaus Tschira) and venture capital and state-backed firms LSP Life Sciences Partners, Forbion Capital, BioMedInvest, CD Venture and KfW and angel investors.

Curetis has raised €49.1m in equity capital to date after a €34m A round in October 2011, which also included Roche Venture Fund.

Curetis will use the B round to test its Unyvero product in more than 50 hospitals. Alexander Asam, investment adviser at HBM Partners, who has joined Curetis’ board, said: “We consider Curetis´ Unyvero Solution to be…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?